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Abstract
Background: To predict the effectiveness of topical glaucoma medications based on initial
uniocular and binocular treatment. To test a traditional hypothesis that effectiveness following a
uniocular trial is associated with the change in IOP in the initially treated eye minus the change in
the initially untreated eye. To determine whether uniocular or binocular treatment trials are
superior.
Methods: Based on a review of medical records, we identified 168 instances in 154 patients with
bilateral primary open angle glaucoma of initial uniocular use of a topical glaucoma medication with
well-documented intraocular pressure (IOP) readings at baseline (IOPA), during the trial (IOPB),
and at follow-up (IOPC). Abstracted data included demographic data, IOP, and medication use.
Predictors of the IOP following the trial (IOPC) in each eye were identified by multivariable linear
regression. In 70 cases, the predictive ability of initial uniocular and binocular treatment could be
directly compared.
Results: In a multivariable analysis, the follow-up pressure in the initially treated eye (IOP1C) was
directly correlated with treated eye IOP during initial uniocular use (IOP1B, p < 0.001). In a
multivariable analysis, the follow-up pressure in the initially untreated eye (IOP2C) was directly
correlated with its baseline IOP2A (p < 0.001), and also tended to be associated with treated IOP1B
(p = 0.07). The multivariable regression coefficient (b) for the IOP change in the initially untreated
eye was generally not close to the value of -1 expected by the classic teaching (for eye 1, b = 0.04,
p = 0.35; for eye 2, b = 0.07, p = 0.50). In 70 cases, the uniocular and binocular trials predicted a
similar fraction of the variance in follow-up IOP1C (r2 = 0.56 and 0.57, respectively) and IOP2C (r2 =
0.39 and 0.38, respectively).
Conclusion: 1) For uniocular trials, the IOP change in the untreated eye should not be subtracted
from that in the treated eye. 2) Uniocular and binocular trials have similar predictive value when
interpreted correctly. Either may be selected based on clinical circumstances.
Background
Most authorities recommend a trial of topical glaucoma
medications which are intended for long-term use in
order to assess patient-specific effectiveness and tolerabil-
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ity. Classically, a uniocular drug trial has been recom-
mended [1-3]. Drug effectiveness is felt to be related to the
change in intraocular pressure (IOP) in the treated eye
minus the change in IOP in the untreated eye [1,3-5].
Using the untreated eye as a control is thought to remove
correlated variability due to diurnal fluctuation [1,4],
operator technique, tonometer calibration, etc.
More recently, several objections to the uniocular drug
trial have been raised. First, some glaucoma agents are
known to have a significant crossover effect [6]. Second,
spontaneous or diurnal IOP fluctuations in each eye
appear to be poorly correlated [7-9]. Third, one study sug-
gested that treatment effect in the first eye during a
monocular trial is only weakly associated with treatment
effect in the second eye [10]. These findings have led some
investigators to suggest that the uniocular drug trial be
abandoned [10,11] or modified [7,8,12], but these calls
have not been universally accepted [13,14].
We performed a retrospective review of patients undergo-
ing initiation of topical glaucoma therapy. The objectives
were to determine: 1) how the information from uniocu-
lar and binocular trials can best be used to determine
medication effectiveness, and 2) whether uniocular and
binocular trials are equally successful at predicting medi-
cation effectiveness. We specifically sought to determine
whether the classical teaching that effectiveness following
a uniocular trial is related to the change in the treated eye
minus the change in the untreated eye, where the
untreated eye serves as a control.
Methods
This study was in compliance with the Helsinki Declara-
tion and was approved by the Office of Research Subjects
Protection Institutional Review Board at Virginia Com-
monwealth University, Medical College of Virginia cam-
pus.
Medical records of glaucoma patients seen at the Medical
College of Virginia were retrospectively reviewed. Inclu-
sion criteria for eligible patients included: age over 18
years, diagnosis of bilateral primary open angle glaucoma,
and initiation of topical glaucoma treatment initially in
one eye with documented intraocular pressures by appla-
nation in both eyes at each of three major time points.
These time points included one or more baseline visits
(time A), a uniocular treatment trial (time B), and during
one or more follow-up visits (time C). The baseline visits
occurred less than one year before the uniocular trial, and
involved identical glaucoma treatments, with the excep-
tion of the uniocular trial treatment. The follow-up visits
occurred less than one year following the uniocular trial,
and involved identical glaucoma treatments, except that
the trial treatment may have been used binocularly during
follow-up.
Before this analysis was presented in 2003 at the Associa-
tion for Research in Vision and Ophthalmology, it was
standard practice by the residents and the majority of
attendings at our institution to begin treatment with a
uniocular trial. An obvious exception was when the phy-
sician felt that the IOP was bilaterally elevated to the
degree that it would be unsafe to leave a control eye
untreated.
When assessing drug effectiveness during a uniocular trial,
it was standard clinical practice to subtract the IOP change
in the untreated eye from the IOP change in the treated
eye to account for diurnal and other correlated fluctua-
tion. The standard practice and clinical judgment of the
treating physician guided all treatment decisions, includ-
ing whether to perform a uniocular trial, which eye to
treat during the uniocular trial, and whether to treat bin-
ocularly on subsequent visits.
For several patients, a uniocular trial and follow-up visit
data were obtained, but on subsequent visits, the physi-
cian decided to add an additional pressure-lowering agent
with another uniocular trial. As long as satisfactory base-
line and follow-up visit data were available, both trials
were included in the data set. In general, the presence of
concurrent glaucoma treatment was not an exclusion cri-
terion. Patients on additional medications were included
because advocates of uniocular or binocular trials have
not stated that either type of trial only works for the first
topical agent, but not for subsequent agents. It was con-
firmed that presence of concurrent topical glaucoma
agents did not alter the study findings by analyzing sepa-
rately trials in which the patients were treated and
untreated at baseline.
In a subset of patients, uniocular and binocular trials
could be directly compared in a secondary analysis
because the uniocular treatment trial (visit B1) was fol-
lowed by binocular use (visit B2), and then by additional
follow-up visits with binocular medication use (time C).
Data collected from the medical records included demo-
graphic information, eye medications, and IOP. Predic-
tors of the followup intraocular pressure in the initially
treated eye (IOP1C), and the second eye (IOP2C), follow-
ing a uniocular or binocular trial were evaluated by mul-
tivariable linear regression analysis. Potential predictors
included the intraocular pressure in both eyes at baseline,
and in eye 1 during initial treatment, and the change in
IOP in the initially untreated eye. Regression residuals
were plotted against the predicted values and the inde-
pendent variables to verify an absence of correlations and
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to verify constancy of the variability of residuals [15]. Sta-
tistica software (version 7, Statsoft Inc., Tulsa OK) was
used to determine the coefficient of determination (r2),
the regression coefficient (b), normality of dependent var-
iables by the Shapiro-Wilk test, and statistical significance
values (p).
For the average follow-up IOP in the first treated eye, the
degree of normality (Shapiro-Wilk p = 0.053) was
improved by logarithmic (p = 0.54) transformation and
improved even more by square root transformation (p =
0.66). Therefore, all analyses were repeated after square
root transformation of the follow-up IOP values. Almost
identical p and r2 values were obtained with transformed
analyses. Moreover, the relative weighting of terms was
very similar. Logarithmic transformation of the IOP [16]
also yielded nearly identical results. Because the conclu-
sions were unchanged with transformation, and because
the untransformed analyses provide the most direct com-
parison with classical teachings, the untransformed anal-
yses are presented. However, the relevant p and r2 values
for the square root transformed analyses are presented to
demonstrate the equivalence of the results.
Results
One hundred sixty-eight eligible uniocular trials in 154
patients were identified and included in the analysis. A
subset of 70 trials in 68 subjects involved uniocular use
followed by binocular use for two or more visits.
Of the 168 uniocular trials, 44% were in males, and 78%
were in black patients (Table 1). This finding simply
reflects the demographic makeup of the university prac-
tice in an urban setting. The mean age was 62.7 years
(Table 2). The medications used in the trial are listed in
Table 1. The average intraocular pressure in the first eye
fell from 20.2 mmHg at the final baseline visit (A), to 15.3
mmHg during the uniocular trial (visit B), and then
increased slightly to 16.1 mmHg during follow-up (time
C, Table 1). The average intraocular pressure in the second
eye gradually decreased from 18.3 mmHg at the final
baseline visit (A), to 17.4 mmHg during the uniocular
trial (visit B), and then to 16.3 mmHg during follow-up
(time C, Table 3).
Uniocular trial prediction of first eye IOP
The significant independent predictors of follow-up
IOP1C in the first-treated eye by multivariable analysis
were the most recent baseline IOP1A and the IOP1B during
the trial (p < 0.001, r2 = 0.40, Table 2).
On the whole, the change in second eye IOP during the
trial (IOP2B – IOP2A) was not a significant predictor of fol-
low-up IOP1C (p = 0.35, Table 2). Only for the 24 trials of
dorzolamide was the second eye term significantly posi-
tive (b = 0.14, p = 0.04, Table 2). For brimonidine, the
coefficient tended to be negative (b = -0.27, p = 0.20), but
the magnitude was much smaller than the value of -1 used
in traditional clinical practice.
Uniocular trial prediction of second eye IOP
For the initially untreated eye follow-up IOP2C, the base-
line IOP2A was an independent predictor (p < 0.001) and
the treated IOP1B during the uniocular trial was nearly sig-
nificant (p = 0.07, Table 3). The regression coefficient for
the second-eye IOP change during the trial (IOP2B –
IOP2A) was not close to the value of -1 expected in the
classical teaching (b = 0.07, p = 0.50). In fact, for dorzola-
Table 1: Characteristics of subjects (n = 154) and glaucoma drug trials (n = 168)
Mean (Standard deviation) Number. Percent.
Male sex 68 44%
Black race (n = 142) 111 78%
Trial of:
Latanoprost 86 51%
Timolol only 33 20%
Dorzolamide only 24 14%
Timolol/dorzolamide combination 1 1%
Brimonidine 17 10%
Bimatoprost 6 4%
Pilocarpine 1 1%
Age (years) 62.7 (11.8)
Baseline IOP, eye 1* (mmHg) 20.2 (5.3)
Baseline IOP, eye 2* (mmHg) 18.3 (5.2)
Uniocular trial IOP, eye 1 (mmHg) 15.3 (4.0)
Uniocular trial IOP, eye 2 (mmHg) 17.4 (5.6)
Followup IOP, mean, eye 1 (mmHg) 16.1 (3.4)
Followup IOP, mean, eye 2 (mmHg) 16.3 (4.5)
* Eye 1 is the initially treated eye. Eye 2 is the other eye.
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mide, the coefficient was significantly positive (b = 0.71,
p = 0.03, Table 3).
Comparison of uniocular and binocular trials
In 70 cases, a uniocular trial was followed by at least two
visits with binocular use. The first visit with binocular use
may be regarded as a binocular trial, while IOP on subse-
quent follow-up visits may serve as the dependent analytic
variable. The independent predictors of the average fol-
lowup pressure in the initially treated eye were the eye 1
IOP at baseline and during the uniocular or binocular trial
(Table 4). The models based on uniocular and binocular
use of the medication predicted similar fractions of the
variance (r2 = 0.56 and 0.57, respectively, Table 4). The
change in intraocular pressure in the contralateral eye (2)
during the binocular trial was not a significant independ-
ent predictor (p = 0.16, Table 4).
The ability to predict the second eye IOP also was similar
between uniocular (r2 = 0.39) and binocular trials (r2 =
0.38, Table 5). In these analyses, only the baseline second
eye IOP2A was a significant predictor of second eye final
IOP (p < 0.05, Table 5).
Discussion
There is currently debate in the ophthalmology commu-
nity about whether treatment with topical glaucoma
agents should be initiated in one eye or in both eyes
[7,8,10,12-14]. Classically, it was felt that a more reliable
estimate of drug effect could be obtained with a uniocular
trial. The IOP change in the untreated eye was subtracted
from the change in the treated eye, to account for corre-
lated variation between the eyes.
Table 3: Prediction of the average intraocular pressure during binocular treatment in the initially untreated eye (eye 2) by 
multivariable linear regression.
Cases (n, r2, Intercept). IOP, eye 1 IOP, eye 2
Last baseline. During Trial. Baseline. ...change with uniocular 
trial.
Time A. Time B. Time A. Time B – A.
(b, p) (b, p) (b, p) (b, p, p*)
All cases (96, 0.49, 5.4) (-0.002, 0.98) (0.19, 0.07) (0.42, <0.001) (0.07, 0.50, 0.53)
Baseline untreated (64, 0.47, 5.6) (-0.01, 0.94) (0.14, 0.30) (0.44, 0.004) (0.10, 0.54, 0.55)
Baseline treated (32, 0.56, 4.4) (0.03, 0.82) (0.24, 0.17) (0.41, 0.006) (0.06, 0.72, 0.80)
Latanoprost (56, 0.41, 5.4) (0.05, 0.81) (-0.004, 0.98) (0.50, 0.03) (0.25, 0.19, 0.23)
Timolol only (19, 0.62, 6.0) (0.02, 0.89) (0.47, 0.04) (0.14, 0.47) (0.04, 0.86, 0.72)
Dorzolamide only (8, 0.90, 2.1) (0.38, 0.03) (0.06, 0.84) (0.78, 0.01) (0.71, 0.03, 0.04)
Brimonidine (10, 0.66, 4.6) (0.17, 0.58) (0.04, 0.92) (0.39, 0.23) (0.04, 0.90, 0.86)
*p value for regression to predict square root of IOP, eye 2.
Table 2: Prediction of the average intraocular pressure in the initially treated eye (eye 1) following a uniocular trial by multivariable 
linear regression
Cases (n, r2, Intercept). IOP, eye 1 IOP, eye 2
Last baseline During Trial Change with trial.
Time A Time B Time B – Time A.
(b, p) (b, p) (b, p, p*)
All cases (168, 0.40, 6.9) (0.27, <0.001) (0.24, <0.001) (0.04, 0.35, 0.34)
Baseline untreated (99, 0.44, 6.4) (0.24, 0.002) (0.34, <0.001) (0.07, 0.43, 0.40)
Baseline treated (69, 0.36, 7.9) (0.24, 0.002) (0.20, 0.02) (0.09, 0.10, 0.09)
Latanoprost (86, 0.44, 5.6) (0.37, <0.001) (0.20, 0.09) (0.03, 0.79, 0.80)
Timolol only (33, 0.45, 8.2) (0.22, 0.03) (0.23, 0.06) (0.05, 0.64, 0.70)
Brimonidine (17, 0.51, 3.5) (0.29, 0.06) (0.43, 0.10) (-0.27, 0.20, 0.24)
Dorzolamide only (24, 0.61, 0.7) (0.45, 0.004) (0.48, 0.02) (0.14, 0.04, 0.04)
*p value for regression to predict square root of IOP, eye 1.
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This retrospective review of initiation of topical glaucoma
therapy has demonstrated that: 1) The traditional teach-
ing that for uniocular trials the IOP change in the
untreated eye should be subtracted from that of the
treated eye to control for diurnal and other correlated fluc-
tuations does not universally apply. 2) Uniocular and bin-
ocular trials have similar predictive value when
interpreted correctly, and either may be selected based on
clinical circumstances.
The reference standard for determining drug effectiveness
in an individual patient is to randomly alternate adminis-
tration of the drug or a placebo in a double-masked fash-
ion over multiple visits at which the outcome variable is
assessed (an "n-of-1 trial") [17,18]. With respect to glau-
coma, drug or placebo drops would be randomly admin-
istered and IOP would be recorded. This technique is not
currently standard in the treatment of glaucoma. In this
study, we assumed that the average IOP on treatment, fol-
lowing any uniocular or binocular medication trials,
minus the pre-treatment average IOP, is the best available
estimate of the true drug effect [11]. Because the pre-treat-
ment average IOP is known at the time of the trial, the
only unknown which must be estimated to know the drug
effect is therefore average follow-up IOP. This follow-up
IOP was therefore the primary dependent variable in the
main regression analyses.
Table 5: Predictors of the average intraocular pressure during binocular use in the subsequently treated eye (eye 2) following a 
uniocular trial and subsequent binocular trial of medication by multivariable linear regression.
Cases...trial type (r2, r2*, Intercept). IOP, eye 1 IOP, eye 2
Last baseline. During Trial. Baseline. Change with trial.
Time A Time B Time A Time B – A.
(b, p) (b, p) (b, p) (b, p)
All cases (n = 70). Trial type...
...uniocular (0.39, 0.39, 5.4) (0.11, 0.27) (0.16, 0.22) (0.33, 0.008) (0.13, 0.37)
...binocular (0.38, 0.39, 6.0) (0.17, 0.14) (-0.10, 0.60) (0.51, 0.003) (0.35, 0.12)
Baseline untreated (n = 48). Trial type...
...uniocular (0.40, 0.42, 4.8) (0.04, 0.80) (0.15, 0.40) (0.44, 0.03) (0.12, 0.57)
...binocular (0.40, 0.43, 5.0) (0.07, 0.70) (-0.09, 0.72) (0.67, 0.008) (0.35, 0.24)
Baseline treated (n = 22). Trial type...
...uniocular (0.37, 0.36, 6.8) (0.14, 0.31) (0.12, 0.60) (0.28, 0.10) (0.19, 0.43)
...binocular (0.37, 0.36, 7.9) (0.24, 0.17) (-0.19, 0.58) (0.42, 0.09) (0.38, 0.28)
* r2 value for regression to predict square root of IOP, eye 2.
Table 4: Predictors of the average intraocular pressure in the initially treated eye (eye 1) following a uniocular trial and subsequent 
binocular trial of medication by multivariable linear regression.
Cases...trial type (r2, r2*, Intercept). IOP, eye 1 IOP, eye 2
Last baseline. During Trial. Baseline. Change with trial.
Time A Time B Time A Time B – A.
(b, p) (b, p) (b, p) (b, p)
All cases (n = 70). Trial type...
...uniocular (0.56, 0.55, 4.5) (0.38, <0.001) (0.29, 0.02) (-0.005, 0.96) (-0.10, 0.41)
...binocular (0.57, 0.57, 3.6) (0.45, <0.001) (0.07, 0.70) (0.20, 0.16) (0.27, 0.16)
Baseline untreated (n = 48). Trial type...
...uniocular (0.55, 0.54, 4.7) (0.36, 0.02) (0.26, 0.10) (0.02, 0.89) (-0.10, 0.56)
...binocular (0.56, 0.57, 3.4) (0.39, 0.01) (0.14, 0.51) (0.20, 0.35) (0.22, 0.39)
Baseline treated (n = 22). Trial type...
...uniocular (0.60, 0.59, 3.4) (0.40, 0.006) (0.34, 0.11) (0.02, 0.92) (-0.02, 0.91)
...binocular (0.60, 0.59, 4.3) (0.56, 0.003) (-0.17, 0.61) (0.30, 0.19) (0.44, 0.19)
* r2 value for regression to predict square root of IOP, eye 1.
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Some authors have suggested that the uniocular drug trial
must be abandoned because of crossover drug effect [6],
because the contralateral eye IOP change during a single
visit may not be used as a control due to uncorrelated fluc-
tuations (unrelated to drug effect) [7,9], or because the
drug effect itself may be independent between the two
eyes [10]. Our study addressed these questions regarding
the validity of the uniocular drug trial as traditionally pro-
posed.
The major finding at odds with standard clinical teaching
is that the IOP change in the untreated eye during a uni-
ocular trial should not be subtracted when assessing drug
effectiveness. An example will help to illustrate the impor-
tance of this finding. A typical patient has a baseline IOP
of 25 mmHg in both eyes, treatment is initiated in one
eye, and the follow-up IOP is 20 mmHg in both eyes. The
standard clinical teaching is that the drug is ineffective in
this patient because the bilateral IOP change relates to
diurnal or other correlated fluctuation. However, this
teaching involves several assumptions: the spontaneous
IOP variation is correlated between both eyes and drug
crossover effect is minimal. An additional assumption is
that the patient, day, and eye are selected for initiation of
treatment at random, so that there is no regression to the
mean. According to the classic teaching, the regression
coefficient for the IOP change in the untreated eye is
minus one in these circumstances. When the change in
the untreated eye is subtracted from the change in the
treated eye, it appears that the drug had no effect.
Alternate interpretations can be made if these assump-
tions do not apply. For instance, a bilateral drop in IOP
from 25 to 20 mmHg with uniocular treatment may in
theory also be interpreted as the result of an effective drug
with a substantial crossover effect. If drug crossover is so
substantial that both eyes essentially receive an equal
effect even with unilateral treatment (a theoretical situa-
tion which does not apply to currently available topical
agents), then the drug effect can be estimated by the aver-
age IOP change. As the average change is simply one half
the change in the treated eye plus one half the change in
the untreated eye, the regression coefficient for the IOP
change in the untreated eye would tend to plus one half
with a complete crossover effect.
Another factor which may affect the interpretation is
regression to the mean, which occurs in clinical practice
(and even in many randomized controlled trials) because
glaucoma treatments are only initiated when patients
have an IOP above the target pressure. As the IOP may be
above the target pressure only due to random fluctuation,
as opposed to a true change in the underlying disease
process, subsequent visits may see a drop in IOP simply
due to the statistical phenomenon known as regression to
the mean. This phenomenon applies to both uniocular
and binocular trials in clinical practice. In uniocular trials
it occurs not only because the average IOP may be high on
a particular visit, but also because most clinicians (and
randomized trial protocols [19]) choose the eye with the
higher IOP for initial treatment. Regression to the mean
likely explains much of the 5% drop in IOP seen with pla-
cebo treatment in randomized trials [20]. It is possible to
reduce regression to the mean in a research setting by
selecting random patients, asking them to come to the
clinic on random days, and initiating treatment in one eye
or in both eyes at random, regardless of whether the
patient appears to need additional treatment. Such a pro-
tocol may have research value but involves initiating ther-
apy in patients already below their target pressure.
Because physicians only treat patients who appear to need
treatment, regression to the mean is a fact of life with
which clinicians must contend when trying to understand
clinical observations. The statistical coefficients derived in
this study allow clinicians to make predictions which take
into account regression to the mean.
In most analyses, the IOP change in the untreated eye dur-
ing a uniocular trial had minimal predictive value and the
regression coefficient was close to zero. For dorzolamide,
the change in IOP in the untreated eye had significant pre-
dictive value, but in the direction opposite from the stand-
ard clinical teaching. Although a more positive coefficient
might suggest the importance of crossover effects with
dorzolamide [21], the number of dorzolamide trials was
small and this finding may be due to chance.
Our data indicate that the uniocular drug trial need not be
abandoned in all cases. However, the interpretation of the
uniocular trial must be modified. After a uniocular trial,
regression equations may be used to predict the IOP in the
first eye (Tables 2) and in the second eye (Table 3). Like-
wise, after a binocular trial, regression equations may be
used to predict the IOP in the first (Table 4) or second eye
(Table 5). When interpreted correctly, both uniocular and
binocular trials had similar success in predicting the
future IOP in the first or second eye.
Whether a uniocular or binocular trial is performed
depends on a variety of circumstances. From the stand-
point of safety, the uniocular trial has advantages because
the patient presumably will receive half the dose systemi-
cally, and because any local allergy or intolerance will be
more easily diagnosed by its uniocular presence. Drug tol-
erability was an important aspect of initial calls for uni-
ocular trials [2]. On the other hand, the binocular drug
trial succeeds in providing benefit to both eyes more
quickly and may spare the patient an additional visit.
Moreover, a binocular trial is less confusing because it
avoids subsequent regimen changes, and because the
BMC Ophthalmology 2007, 7:17 http://www.biomedcentral.com/1471-2415/7/17
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patient need not remember which drug is initially taken
uniocularly and which eye is treated.
This study had a number of limitations. First, several sub-
jects contributed more than one trial with different types
of medication even though the results of two trials of dif-
ferent medications in one individual might not be com-
pletely independent. This objection is largely addressed
by the subset of trials comparing uniocular and binocular
trials because only two of the 68 subjects contributed
more than one medication trial. Finally, as with previous
studies [9-11], the data were retrospective and patient
compliance may have been imperfect. On the other hand,
the data reflect real-world observations made in an urban
university glaucoma practice, and may apply to similar
practices.
One problem highlighted by our data is that a single-visit
uniocular or binocular drug trial still leaves a great deal of
unexplained variation in follow-up IOP. Even combining
the information from two visits (a uniocular and binocu-
lar trial) had minimal added benefit in terms of the ability
to predict IOP (data not shown). Some authors have
hypothesized that plotting the diurnal variation in indi-
vidual patients might make estimation of drug effect with
uniocular trials more accurate [7,8,12,22]. Others have
advocated multiple baseline and follow-up visits in the
context of binocular drug trials [11]. Undoubtedly, addi-
tional visits will permit better predictions for both uni-
ocular and binocular drug trials, but a quantitative
understanding of the improvement is lacking. Additional
studies will be needed to test specific protocols. Given the
difficulty of assessing patient-specific therapeutic effect, in
the future appropriate medication selection may also be
based in part on genetic testing [23].
Conclusion
To briefly summarize, our study showed that the change
in IOP in the untreated eye during a uniocular trial does
not generally provide significant predictive information.
Either uniocular or binocular trials may be performed in
appropriate clinical circumstances.
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